HOME >> MEDICINE >> NEWS
Study shows Philip Morris pursued tobacco regulation to enhance its image

A new study by UCSF School of Nursing researchers shows that Philip Morris sought to enhance its image by supporting Food and Drug Administration regulation of tobacco.

Philip Morris was among major U.S. tobacco companies that previously sued the FDA when it attempted to regulate nicotine as a drug and cigarettes as nicotine delivery devices, but beginning in 2000, the company began aggressively pursuing FDA regulation.

"With image-shaping in mind, PM devoted enormous resources to achieving regulation--but on its own terms," says senior study author Ruth Malone, RN, PhD. "While health advocates frame tobacco use as a public health policy issue, PM's regulatory efforts focused on framing tobacco use as an individual choice by informed adults to take a risk, which allowed the company to portray itself as a reasonable and responsible manufacturer of a risky product."

The plan was to divide public health groups and to set Philip Morris apart from other companies in an effort to achieve favorable regulation from a Republican-dominated Congress, according to Malone, who is an associate professor in the UCSF School of Nursing.

The study is published in the June 2005 issue of the international journal Tobacco Control. First author is Patricia McDaniel, a postdoctoral fellow at the Center for Tobacco Control Research and Education at UCSF.

Malone and McDaniel based their study on previously secret internal tobacco industry documents. Most of these papers have become available through litigation and now are available at the Legacy Tobacco Documents Library at UCSF.

In their analysis, the researchers show that the change in position was part of a broad effort to redefine the company as socially responsible. The company worked closely with federal legislators, conducted polls contrasting two extremes to make it appear that the public supported their position, and engaged in an extensive public relations campaign to win the pu
'"/>

Contact: Corinna Kaarlela
ckaarlela@pubaff.ucsf.edu
415-476-2557
University of California - San Francisco
24-May-2005


Page: 1 2

Related medicine news :

1. Study, meta-analysis examine factors associated with death from heatstroke
2. Study says COPD testing is not measuring up
3. Study suggests loss of 2 types of neurons -- not just 1 -- triggers Parkinsons symptoms
4. Study reveals gaps in vaccine financing for underinsured children
5. Study suggests nonpharmaceutical interventions may be helpful in severe influenza outbreaks
6. Study shows radiofrequency ablation highly effective in treating kidney tumors
7. Study says normal but out-of-control enzyme may be culprit that signals some cells to become cancer
8. Study finds HIV protease inhibitor drugs may adversely affect the scaffolding of the cell nucleus
9. Study outlines how stroke, head injury can increase risk of Alzheimers disease
10. Study identifies new regulator of fat metabolism
11. Study shows Diachrome improves blood sugar control in people with type 2 diabetes

Post Your Comments:
(Date:6/19/2013)... The former internist for the St. Louis ... serves as director of prevention and wellness at St. ... personal encounter with a metabolic syndrome diagnosis and a ... , that he credits with sparking the paradigm-shift that ... practice. , “The average medical student gets 30 minutes ...
(Date:6/19/2013)... Recently, SoCal CEO Magazine staff was on hand ... in a series of six workshops where people with and without ... the mosaic tiles in their permanent location under the direction of ... Maxwell. , This mural project began in March of 2013 ... three years ago with the goal of promoting ...
(Date:6/19/2013)... The US Food and Drug Administration (FDA) announced ... breast implant, Mentor Worldwide’s MemoryShape™. , The FDA approved Sientra/Silimed ... FDA announced the approval of the MemoryShape™ implant on June ... in women 22 years old or older and in ... FDA’s approval comes after six years of data from 955 ...
(Date:6/19/2013)... the mantra of neurologists treating stroke victims has been "time ... room quickly to receive a drug that dissolves the stroke-causing ... brain tissue is saved or lost. , But ... of giving the intravenous drug known as a tissue ... ischemic (clot-caused), stroke, the most common type of stroke. ...
(Date:6/19/2013)... fact that the incidence of cancer is many fold ... still have an inadequate understanding on how best to ... patients are occasionally included in clinical trials, those elderly ... elderly patients. Thus, the broader elderly patient population is ... in the Elderly Task Force is now starting a ...
Breaking Medicine News(10 mins):Health News:Plant-based Nutrition is Key to Health Transformation of St. Luke’s Hospital Director of Prevention and Wellness 2Health News:Plant-based Nutrition is Key to Health Transformation of St. Luke’s Hospital Director of Prevention and Wellness 3Health News:Arc Creates Huge Mosaic Mural to Highlight the Need for Greater Respect of People with Disabilities 2Health News:FDA Approved Mentor® MemoryShape™ Breast Implants Now Offered to Patients at Swan Center for Plastic Surgery 2Health News:Timely treatment after stroke is crucial, UCLA researchers report 2Health News:Timely treatment after stroke is crucial, UCLA researchers report 3Health News:EORTC study opens for elderly patients with HER-2 positive metastatic breast cancer 2
(Date:6/19/2013)... June 19, 2013   Life Technologies Corporation ... licensing agreement granting Suzhou Ribo Life Sciences (Ribo) ... therapeutics in China using ... proprietary siRNA molecules in combination with Invivofectamine® Rx ... human diseases with high unmet medical need in ...
(Date:6/19/2013)... 19. Juni 2013 Specialty ... der Entwicklung von SCS microRESIST™, einer ... der Beschichtung mit Parylene gelungen ist. ... biokompatiblem Parylene mit antimikrobiellen Eigenschaften und ... Mikroorganismen auf beschichteten medizinischen Geräten. ...
(Date:6/18/2013)... 18, 2013  Intercept Pharmaceuticals, Inc.  (NASDAQ: ... the development and commercialization of novel bile acid therapeutics ... of an underwritten public offering of 1,730,000 shares of ... $33.01 per share.  In addition, Intercept has granted the ... additional 259,500 shares of common stock. All ...
Breaking Medicine Technology:Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China 2Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China 3Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China 4Specialty Coating Systems gibt die Einführung einer neuen antimikrobiellen Parylene-Technologie bekannt 2Intercept Pharmaceuticals Announces Pricing of Public Offering of Common Stock 2
Cached News: